• Home
  1. Home
  2. Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment
Scientific article
English

Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment

ContributorsFerrari, Serge Livio; Butler, Peter W; Kendler, David L; Miller, Paul D; Roux, Christian; Wang, Andrea T; Huang, Shuang; Wagman, Rachel B; Lewiecki, E Michael
Published inJournal of Clinical Endocrinology and Metabolism, vol. 104, no. 8, p. 3450-3461
Publication date2019
Abstract

CONTEXT: Evidence for further nonvertebral fracture (NVF) reductions with long-term antiresorptive therapy in osteoporosis is lacking. OBJECTIVE: To evaluate NVF risk reduction in subjects receiving ≤10 years of denosumab treatment. DESIGN: Phase 3, randomized, placebo-controlled, 3-year Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial (NCT00089791) and its open-label 7-year extension (NCT00523341).

Affiliation entities
Research groups
Citation (ISO format)
FERRARI, Serge Livio et al. Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. In: Journal of Clinical Endocrinology and Metabolism, 2019, vol. 104, n° 8, p. 3450–3461. doi: 10.1210/jc.2019-00271
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Additional URL for this publicationhttps://academic.oup.com/jcem/article/104/8/3450/5497103
Journal ISSN0021-972X
353views
1downloads

Technical informations

Creation26/07/2019 10:56:00
First validation26/07/2019 10:56:00
Update15/03/2023 18:06:06
Status update15/03/2023 18:06:05
Last indexation31/10/2024 16:24:21
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack